Provided by Tiger Trade Technology Pte. Ltd.

Biogen

215.30
+4.572.17%
Volume:340.01K
Turnover:72.82M
Market Cap:31.79B
PE:38.24
High:216.30
Open:209.92
Low:208.93
Close:210.73
52wk High:225.80
52wk Low:135.39
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.96
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.69
PE(LYR):24.49

Loading ...

Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data

TIPRANKS
·
Aug 12

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 11

Kailera Therapeutics Names Nur Nicholson Chief Technology Officer

Reuters
·
Aug 11

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 10

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

GlobeNewswire
·
Aug 10

Should Biogen’s Profit Squeeze Amid Rising New-Therapy Sales Prompt Action From Biogen (BIIB) Investors?

Simply Wall St.
·
Aug 09

Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab

TIPRANKS
·
Aug 08

Biogen completes acquisition of RayThera

TIPRANKS
·
Aug 07

Biogen Completes Acquisition of RayThera

Reuters
·
Aug 07

Biogen Completes Acquisition of Raythera Inc.

THOMSON REUTERS
·
Aug 07

Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story

TIPRANKS
·
Aug 07

Biogen Director Lloyd Minor Disposes of 1,186 Common Shares Worth $240,351.94

Reuters
·
Aug 06

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Biogen price target raised to $241 from $221 at Mizuho

TIPRANKS
·
Aug 04

From Products to Innovation: Three Emerging Sectors Anchor China's Economic Growth in 2025

Deep News
·
Aug 04

Stoke Therapeutics Q2 Revenue Falls 33% on Lower Collaboration, Licensing Income

Reuters
·
Aug 04

Biogen is Maintained at Neutral by Citigroup

Dow Jones
·
Aug 04

Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)

TIPRANKS
·
Aug 03

Biogen : Citigroup Raises Target Price to $215 from $200

THOMSON REUTERS
·
Aug 03

Stifel Nicolaus Remains a Buy on Biogen (BIIB)

TIPRANKS
·
Aug 03